AVIEW: Comprehensive AI for chest CT
Coreline Soft’s AVIEW platform offers a suite of AI tools for thoracic CT analysis—covering lung cancer screening, emphysema, calcification, and interstitial lung disease.
The solution streamlines radiology workflows by automatically segmenting structures, generating quantifiable reports, and aiding in consistent diagnosis.
With FDA 510(k) clearance and CE marking, AVIEW is deployed in clinical settings worldwide—backed by peer-reviewed studies and integrations at major institutions.
Key benefits
- Detects and quantifies lung nodules, COPD, coronary calcium, and ILD in low-dose chest CT
- Reduces variability and speeds up reporting with automated segmentation & analysis
- Fully certified: FDA 510(k), CE-MDR (Class IIb), PMDA, TGA, Health Canada, HSA Singapore
Details
- Regulatory: FDA 510(k) cleared, CE Class IIb under MDR, approvals across US, EU, Canada, Australia
- Applications: Lung cancer screening, COPD assessment, Coronary Artery Calcium scoring, ILD/ILD pattern analysis
- Modality: Chest CT (low-dose, non-gated)
- Body part: Lungs, coronary arteries, thoracic region
Clinical evidence
- AVIEW LCS+ in 90+ institutions, used for nationwide lung cancer screening in Korea since 2017
- Peer-reviewed validation: high reliability in CAC scoring on low-dose CT, published in JACC and European Radiology
For the latest clinical evidence and updates, visit the company’s official website: https://www.corelinesoft.com/en/
Ask K2AI how Coreline Soft AVIEW can bring complete AI-driven chest CT analysis into your radiology workflow.
בניית אתרים JUNAMI